American Century Companies Inc. Acquires 108,127 Shares of Edwards Lifesciences Corporation $EW

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. boosted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,274,184 shares of the medical research company's stock after acquiring an additional 108,127 shares during the period. American Century Companies Inc. owned 0.22% of Edwards Lifesciences worth $92,353,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $49,038,000. Dynamic Advisor Solutions LLC boosted its holdings in shares of Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after buying an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares in the last quarter. Finally, Advanced Portfolio Management LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $328,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on EW shares. Citigroup restated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Evercore ISI increased their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Finally, Truist Financial increased their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $85.90.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the sale, the vice president directly owned 50,356 shares of the company's stock, valued at approximately $3,897,554.40. This represents a 4.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 24,584 shares of company stock valued at $1,897,762. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE:EW traded up $0.5950 during trading on Friday, reaching $81.7550. 2,088,142 shares of the stock were exchanged, compared to its average volume of 4,511,915. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The stock has a fifty day moving average of $77.45 and a two-hundred day moving average of $74.60. The firm has a market cap of $48.00 billion, a price-to-earnings ratio of 11.76, a price-to-earnings-growth ratio of 3.93 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.